Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ESICM UNITE COVID-19 Project (UNITE-COVID) (UNITE-COVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04836065
Recruitment Status : Completed
First Posted : April 8, 2021
Last Update Posted : April 8, 2021
Sponsor:
Collaborator:
European Society of Intensive Care Medicine
Information provided by (Responsible Party):
University Hospital, Ghent

Brief Summary:

COVID-19 is arguably the biggest challenge critical care medicine has been confronted with since its conception. Critical care services around the world are flooded by patients presenting with severe respiratory failure who require prolonged treatment in the ICU. Despite the support provided, outcomes are poor, particularly in ventilated patients.

Many unanswered questions remain regarding the pathophysiology of COVID-19, particularly in severely ill patients. No evidence-based treatment is currently available, yet different often experimental therapies are administered to patients.

As experience grows, new phenotypes are recognized, and unreported complications are observed in the most severely ill patients. Although many registries are currently including patients, few of them focus on ICU patients and their specific treatments and newly observed complications and challenges.

Although the pandemic may appear on its return in many countries that are now easing the restrictions that were put in place to limit the spread of the disease, it can be expected that COVID-19 will be a continued challenge in ICUs globally until a safe and effective vaccine is found. Efforts to study the disease should continue in order to advance our understanding of the disease as well as improve treatment options.


Condition or disease
COVID-19 Infection

Detailed Description:

This is a multicenter, international, anonymized point prevalence study. Patients who were present in the ICU on the day in April 2020 with the highest number of COVID-19 patients in the unit. Data can be entered in the database until July 2020. Retrospective data collection and entry is allowed.

Subjects believed to fulfill all eligibility criteria, and none of the exclusion criteria, detailed in the relevant section of this protocol, will be included in the study.

Data will be entered in the database anonymously.

Data will consist of two core elements:

  1. Center data (to be completed once)
  2. Patient data

For different domains with specific, highly relevant and un(der)explored ICU research questions, an focused data set is to be completed. These domains include:

  1. Respiratory
  2. Coagulation and thrombo-embolic events
  3. Infectious complications
  4. Rehabilitation
  5. Renal

Layout table for study information
Study Type : Observational
Actual Enrollment : 4995 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: European Society Of Intensive Care Medicine COVID-19 Project (UNITE-COVID)
Actual Study Start Date : July 1, 2020
Actual Primary Completion Date : September 30, 2020
Actual Study Completion Date : December 31, 2020



Primary Outcome Measures :
  1. Number of patients admitted with confirmed COVID19 infection [ Time Frame: One day with 60 day follow-up ]
    Number of patients in the ICU on the study day

  2. Mortality (ICU) [ Time Frame: One day with 60 day follow-up ]
    Proportion of patients who have died at ICU discharge

  3. Mortality (60-day) [ Time Frame: One day with 60 day follow-up ]
    Proportion of patients who have died at day 60


Secondary Outcome Measures :
  1. Duration of hospitalization in the ICU [ Time Frame: One day with 60 day follow-up ]
    Length of stay in the ICU

  2. Proportion of patients requiring invasive mechanical ventilation [ Time Frame: One day with 60 day follow-up ]
    Proportion of patients who require invasive mechanical ventilation during ICU stay versus all patients

  3. Proportion of patients developing infections during ICU stay [ Time Frame: One day with 60 day follow-up ]
    Proportion of patients who acquire an infection during their ICU stay versus all patients

  4. Proportion of patients developing thromboembolic events during ICU stay [ Time Frame: One day with 60 day follow-up ]
    Proportion of patients who develop any thromboembolic event during their ICU stay versus all patients

  5. Proportion of patients requiring tracheotomy during ICU stay [ Time Frame: One day with 60 day follow-up ]
    Proportion of patients who are require a tracheostomy versus all patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with confirmed COVID-19 infection present in the ICUs of participating hospitals or in any other place of the hospital under the care of the critical care team on the day between 15th February 2020 and 15th June 2020 with the highest number of COVID-19 patients in the unit or in any other place of the hospital under the care of the critical care team (date to be decided by local investigator).
Criteria

Inclusion Criteria:

  • Patient is present in an ICU or in any other place of the hospital under the care of the critical care team on the day between 15th February 2020 and 15th June 2020 with the highest number of COVID-19 patients in the unit. The exact date can be decided by the local investigator.
  • COVID-19 confirmed diagnosis through PCR or equivalent diagnostic technique

Exclusion Criteria:

  • Any of the following is regarded as a criterion for exclusion from the study: SARS-CoV2 positive without COVID-19

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04836065


Locations
Layout table for location information
Belgium
Ghent University Hospital
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
European Society of Intensive Care Medicine
Investigators
Layout table for investigator information
Principal Investigator: Jan DE WAELE University of Gent Hospital
Publications:

Layout table for additonal information
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT04836065    
Other Study ID Numbers: ESICMUNITE2020
First Posted: April 8, 2021    Key Record Dates
Last Update Posted: April 8, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Ghent:
Covid-19
Infection
Inflammation
respiratory distress
coagulation
thromboembolus
rehabilitation
renal
cardiac
mobilization
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection